,i #aadth ,,congress #ast ,session ,h4 ,r4 #bdaf ,,in ,,the ,,house ,,of ,,representatives ,may #ai1 #bjae ,mr4 ,burgess introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to evaluate the potential use of evidence from clinical experience to help support the approval of new indications for approved drugs1 and for other purposes4 #a4 ,utilizing evidence from clinical experience ,chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended by inserting after section #eje;,e of such ,act 7#ba ,u4,s4,c4 #cee;f7 the following3 #eje;,f4 ,utilizing evidence from clinical experience 7a7 ,in general ,the ,secretary shall establish a program to evaluate the potential use of evidence from clinical experience-- 7#a7 to help support the approval of a new indication for a drug approved under section #eje7;b72 and 7#b7 to help support or satisfy post-approval study requirements4 7b7 ,evidence from clinical experience defined ,in this section1 the term evidence from clinical experience means data regarding the usage1 or potential benefits or risks1 of a drug derived from sources other than randomized clinical trials1 including from observational studies1 registries1 and therapeutic use4 7c7 ,program framework 7#a7 ,in general ,not later than #ah months after the date of enactment of this section1 the ,secretary shall establish a draft framework for implementation of the program under this section4 7#b7 ,contents of framework ,the framework shall include information describing-- 7,a7 the current sources of data developed through clinical experience1 including ongoing safety surveillance1 registry1 claims1 and patient-centered outcomes research activities2 7,b7 the gaps in current data collection activities2 7,c7 the current standards and methodologies for collection and analysis of data generated through clinical experience2 and 7,d7 the priority areas1 remaining challenges1 and potential pilot opportunities that the program established under this section will address4 7#c7 ,consultation 7,a7 ,in general ,in developing the program framework under this subsection1 the ,secretary shall consult with regulated industry1 academia1 medical professional organizations1 representatives of patient advocacy organizations1 disease research foundations1 and other interested parties4 7,b7 ,process ,the consultation under subparagraph 7,a7 may be carried out through approaches such as-- 7i7 a public-private partnership with the entities described in such subparagraph1 in which the ,secretary may participate2 or 7ii7 a contract1 grant1 or other arrangement1 as determined appropriate by the ,secretary with such a partnership or an independent research organization4 7d7 ,program implementation ,the ,secretary shall1 not later than #bd months after the date of enactment of this section and in accordance with the framework established under subsection 7c71 implement the program to evaluate the potential use of evidence from clinical experience4 7e7 ,guidance for industry ,the ,secretary shall-- 7#a7 utilize the program established in subsection 7d71 its activities1 and any subsequent pilots or written reports1 to inform a guidance for industry on-- 7,a7 the circumstances under which sponsors of drugs and the ,secretary may rely on evidence from clinical experience for the purposes described in subsections 7a77#a7 or 7a77#b72 and 7,b7 the appropriate standards and methodologies for collection and analysis of evidence from clinical experience submitted for such purposes2 7#b7 not later than #cf months after the date of enactment of this section1 issue draft guidance for industry as described in paragraph 7#a72 and 7#c7 not later than #dh months after the date of enactment of this section1 after providing an opportunity for public comment on the draft guidance1 issue final guidance4 7f7 ,rule of construction 7#a7 ,subject to paragraph 7#b71 nothing in this section prohibits the ,secretary from using evidence from clinical experience for purposes not specified in this section1 provided the ,secretary determines that sufficient basis exists for any such non-specified use4 7#b7 ,this section shall not be construed to alter-- 7,a7 the standards of evidence under-- 7i7 subsection 7c7 or 7d7 of section #eje1 including the substantial evidence standard in such subsection 7d72 or 7ii7 section #cea7;a7 of the ,public ,health ,service ,act2 or 7,b7 the ,secretary's authority to require post-approval studies or clinical trials1 or the standards of evidence under which studies or trials are evaluated4 4